Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. Ati-2173
2. At-2173
3. 1951476-79-1
4. Unii-77ap23j0gh
5. L-alanine, N-((s)-hydroxyphenoxyphosphinyl)-, 1-methylethyl Ester, 5'-ester With 1-(2-deoxy-2-fluoro-.beta.-l-arabinofuranosyl)-5-methyl-2,4(1h,3h)-pyrimidinedione
6. L-alanine, N-((s)-hydroxyphenoxyphosphinyl)-, 1-methylethyl Ester, 5'-ester With 1-(2-deoxy-2-fluoro-beta-l-arabinofuranosyl)-5-methyl-2,4(1h,3h)-pyrimidinedione
| Molecular Weight | 529.5 g/mol |
|---|---|
| Molecular Formula | C22H29FN3O9P |
| XLogP3 | 1.2 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 11 |
| Rotatable Bond Count | 11 |
| Exact Mass | 529.16254467 g/mol |
| Monoisotopic Mass | 529.16254467 g/mol |
| Topological Polar Surface Area | 153 Ų |
| Heavy Atom Count | 36 |
| Formal Charge | 0 |
| Complexity | 911 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 6 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
Details:
Following 90 days of dosing, ATI-2173, in combination with tenofovir disoproxil fumarate (TDF), was generally well-tolerated with alanine aminotransferase (ALT) normalization and no ALT flares off-treatment.
Lead Product(s): ATI-2173,Tenofovir Disoproxil Fumarate
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 25, 2022
Lead Product(s) : ATI-2173,Tenofovir Disoproxil Fumarate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Following 90 days of dosing, ATI-2173, in combination with tenofovir disoproxil fumarate (TDF), was generally well-tolerated with alanine aminotransferase (ALT) normalization and no ALT flares off-treatment.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 25, 2022
Details:
ABI-H0731 (Vebicorvir) a first-generation selective inhibition of HBV DNA replication core protein, has demonstrated effective antiviral activity in chronic hepatitis B patients.
Lead Product(s): Vebicorvir,ATI-2173,Tenofovir
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 08, 2022
Lead Product(s) : Vebicorvir,ATI-2173,Tenofovir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Assembly Biosciences to Highlight Data from HBV Core Inhibitor Programs at EASL’s International ...
Details : ABI-H0731 (Vebicorvir) a first-generation selective inhibition of HBV DNA replication core protein, has demonstrated effective antiviral activity in chronic hepatitis B patients.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 08, 2022
Details:
ATI-2173, once-daily, oral drug candidate for treating HBV, is an investigational phosphoramidate prodrug of clevudine monophosphate, only active site polymerase inhibitor nucleotide for HBV in clinical development.
Lead Product(s): ATI-2173,Tenofovir,Vebicorvir
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 26, 2022
Lead Product(s) : ATI-2173,Tenofovir,Vebicorvir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ATI-2173, once-daily, oral drug candidate for treating HBV, is an investigational phosphoramidate prodrug of clevudine monophosphate, only active site polymerase inhibitor nucleotide for HBV in clinical development.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 26, 2022
Details:
The data showed that ATI-2173 alone, or in combination with tenofovir disoproxil fumarate (TDF), was generally well-tolerated among the cohorts, and ATI-2173 and TDF suppressed HBV DNA and induced declines in biomarkers of cccDNA activity.
Lead Product(s): ATI-2173,Tenofovir Disoproxil Fumarate
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 30, 2022
Lead Product(s) : ATI-2173,Tenofovir Disoproxil Fumarate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The data showed that ATI-2173 alone, or in combination with tenofovir disoproxil fumarate (TDF), was generally well-tolerated among the cohorts, and ATI-2173 and TDF suppressed HBV DNA and induced declines in biomarkers of cccDNA activity.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 30, 2022
Details:
ATI-2173 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Hepatitis B, Chronic.
Lead Product(s): ATI-2173,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 28, 2022
Lead Product(s) : ATI-2173,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Ethnobridging Study in Healthy Volunteers, Chinese and Japanese Subjects
Details : ATI-2173 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Hepatitis B, Chronic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 28, 2022
Details:
ATI-2173 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Hepatitis B, Chronic.
Lead Product(s): ATI-2173,Vebicorvir,Tenofovir Disoproxil Fumarate
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 14, 2022
Lead Product(s) : ATI-2173,Vebicorvir,Tenofovir Disoproxil Fumarate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ATI-2173 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Hepatitis B, Chronic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 14, 2022
Details:
ATI-2173 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): ATI-2173,Tenofovir
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 30, 2021
Lead Product(s) : ATI-2173,Tenofovir
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ATI-2173 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 30, 2021
Details:
ATI-2173 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): ATI-2173,Midazolam,Clarithromycin
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 30, 2021
Lead Product(s) : ATI-2173,Midazolam,Clarithromycin
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Drug-Drug Interaction Study Between ATI-2173 and Midazolam or Clarithromycin in Healthy Subjects
Details : ATI-2173 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 30, 2021
Details:
The proceeds from this financing will be used to advance the clinical development of ATI-2173, Antios’ lead Phase 2b clinical candidate. ATI-2173 is the only Active Site Polymerase Inhibitor Nucleotide (ASPIN) in clinical development.
Lead Product(s): ATI-2173,AB-729,Tenofovir Disoproxil Fumarate
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: GordonMD Global Investments
Deal Size: $75.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing November 03, 2021
Lead Product(s) : ATI-2173,AB-729,Tenofovir Disoproxil Fumarate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : GordonMD Global Investments
Deal Size : $75.0 million
Deal Type : Series B Financing
Details : The proceeds from this financing will be used to advance the clinical development of ATI-2173, Antios’ lead Phase 2b clinical candidate. ATI-2173 is the only Active Site Polymerase Inhibitor Nucleotide (ASPIN) in clinical development.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
November 03, 2021
Details:
ATI-2173 has, to date, demonstrated a generally well-tolerated safety profile, leveraging a unique ASPIN mechanism in clinical development to empower combination therapy.
Lead Product(s): ATI-2173,Vebicorvir
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: IND EnablingProduct Type: Miscellaneous
Sponsor: Antios Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 19, 2021
Lead Product(s) : ATI-2173,Vebicorvir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Antios Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Details : ATI-2173 has, to date, demonstrated a generally well-tolerated safety profile, leveraging a unique ASPIN mechanism in clinical development to empower combination therapy.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
October 19, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
52
PharmaCompass offers a list of ATI-2173 API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right ATI-2173 manufacturer or ATI-2173 supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred ATI-2173 manufacturer or ATI-2173 supplier.
A ATI-2173 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of ATI-2173, including repackagers and relabelers. The FDA regulates ATI-2173 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. ATI-2173 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A ATI-2173 supplier is an individual or a company that provides ATI-2173 active pharmaceutical ingredient (API) or ATI-2173 finished formulations upon request. The ATI-2173 suppliers may include ATI-2173 API manufacturers, exporters, distributors and traders.
ATI-2173 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of ATI-2173 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right ATI-2173 GMP manufacturer or ATI-2173 GMP API supplier for your needs.
A ATI-2173 CoA (Certificate of Analysis) is a formal document that attests to ATI-2173's compliance with ATI-2173 specifications and serves as a tool for batch-level quality control.
ATI-2173 CoA mostly includes findings from lab analyses of a specific batch. For each ATI-2173 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
ATI-2173 may be tested according to a variety of international standards, such as European Pharmacopoeia (ATI-2173 EP), ATI-2173 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (ATI-2173 USP).
